Fennec Pharmaceuticals (FENC) Non Operating Income (2010 - 2025)
Fennec Pharmaceuticals posted quarterly Non Operating Income of -$2.1 million for Q4 2025, down 208.91% year-on-year from $2.0 million in Q4 2024, and down 373.72% on a QoQ basis from -$449000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) has 16 years of Non Operating Income data on file, last reported at -$2.1 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 208.91% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2025 stood at -$3.4 million (changed N/A YoY), and the FY2025 full-year result was -$3.4 million, changed N/A from the prior year.
- Non Operating Income for Q4 2025 stood at -$2.1 million, down from -$449000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $2.0 million in Q4 2024 and bottomed at -$2.1 million in Q4 2025.
- The 5-year median for Non Operating Income is -$434500.0 (2025), against an average of -$393750.0.
- The widest annual swing landed in 2021, when Non Operating Income jumped 2211.11%; it then slumped 1483.33% in 2022.
- A 5-year view of Non Operating Income shows it stood at -$220000.0 in 2021, then slumped by 228.18% to -$722000.0 in 2022, then dropped by 19.67% to -$864000.0 in 2023, then jumped by 326.04% to $2.0 million in 2024, then plunged by 208.91% to -$2.1 million in 2025.
- The last three Non Operating Income figures came in at -$2.1 million (Q4 2025), -$449000.0 (Q3 2025), and -$420000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Fennec Pharmaceuticals | 281.48 Mn | 244.70 Mn | 7.67 Mn | -2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.13 Mn |
| Sep 30, 2025 | -449,000.00 |
| Jun 30, 2025 | -420,000.00 |
| Mar 31, 2025 | -357,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | -533,000.00 |
| Jun 30, 2024 | -514,000.00 |
| Mar 31, 2024 | -906,000.00 |
| Dec 31, 2023 | -864,000.00 |
| Sep 30, 2023 | -850,000.00 |
| Jun 30, 2023 | -778,000.00 |
| Mar 31, 2023 | -782,000.00 |
| Dec 31, 2022 | -722,000.00 |
| Sep 30, 2022 | -190,000.00 |
| Jun 30, 2022 | -63,000.00 |
| Mar 31, 2022 | -150,000.00 |
| Dec 31, 2021 | -220,000.00 |
| Sep 30, 2021 | -12,000.00 |
| Jun 30, 2021 | -81,000.00 |
| Mar 31, 2021 | 190,000.00 |
| Dec 31, 2020 | -220,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 13,000.00 |
| Mar 31, 2020 | -9,000.00 |
| Dec 31, 2019 | 43,000.00 |
| Sep 30, 2019 | 54,000.00 |
| Jun 30, 2019 | -10,000.00 |
| Mar 31, 2019 | 54,000.00 |
| Dec 31, 2018 | 6,000.00 |
| Sep 30, 2018 | 99,000.00 |
| Jun 30, 2018 | 78,000.00 |
| Mar 31, 2018 | -3,000.00 |
| Dec 31, 2017 | 312,000.00 |
| Sep 30, 2017 | 1,000.00 |
| Jun 30, 2017 | -4,000.00 |
| Mar 31, 2017 | -1,000.00 |
| Dec 31, 2016 | -2,000.00 |
| Jun 30, 2016 | -17,000.00 |
| Mar 31, 2016 | 34,000.00 |
| Dec 31, 2015 | 1.24 Mn |
| Sep 30, 2015 | 215,000.00 |
| Jun 30, 2015 | 376,000.00 |
| Mar 31, 2015 | 629,000.00 |
| Dec 31, 2014 | 704,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 180,000.00 |
| Mar 31, 2014 | -2.66 Mn |
| Dec 31, 2013 | 1.53 Mn |
| Sep 30, 2013 | -1.72 Mn |
| Jun 30, 2013 | 7.53 Mn |
| Mar 31, 2013 | -3.57 Mn |
| Dec 31, 2012 | -5.39 Mn |
| Sep 30, 2012 | -134,000.00 |
| Jun 30, 2012 | 648,000.00 |
| Mar 31, 2012 | 3.33 Mn |
| Dec 31, 2011 | 4.41 Mn |
| Sep 30, 2011 | -2.20 Mn |
| Jun 30, 2011 | 224,000.00 |
| Mar 31, 2011 | 5.69 Mn |
| Dec 31, 2010 | -5.77 Mn |
| Sep 30, 2010 | 2.61 Mn |
| Jun 30, 2010 | -64,000.00 |